SILGAN HOLDINGS INC Q3 FY2026 earnings call

Strategic Portfolio Transformation:

• Announced a transformative plan to split into two companies: Silgan MCC (Metal Containers & Custom) and Silgan DS (Dispensing Solutions), following the proposed acquisition of Trivium.
• Transaction expected to close mid-2027, aiming to unlock higher growth profiles for each entity.

Operational Resilience & Growth:

• Delivered record adjusted EPS at the high end of guidance despite challenging consumer demand and inflation.
• Dispensing segment saw double-digit growth in North American prescription pharma products, now a ~$250 million revenue stream.
• Fragrance products maintained mid-single-digit volume growth, winning disproportionate new product launches through innovation.
• Metal containers benefited from completed cost reduction initiatives ($50 million saved) and normalized fruit/vegetable pack planning.

Cost Management:

• Implemented aggressive pricing actions in Dispensing and Specialty Closures to recover non-contractual inflation, with effects flowing through in Q4 and beyond.
• Maintained tight contractual pass-throughs for raw materials in Metal Containers and Custom Containers.

Financial Discipline:

• Increased full-year adjusted EPS guidance twice during the year.
• Generated favorable interest expense through active treasury management and cash repatriation.
• Reduced corporate expenses by reversing development costs related to the Trivium deal.

Dispensing and Specialty Closures: Sales increased 1% year-over-year to approximately $750 million (estimated based on segment mix), driven by raw material pass-throughs. Volumes were flat, with strong growth in fragrance and pharma offsetting declines in food and beverage. Adjusted EBIT decreased by $2 million due to unrecovered inflation costs expected to be recouped in H2.

Metal Containers: Sales increased 1% year-over-year, primarily from steel and aluminum cost pass-throughs. Volumes declined 4%, negatively impacted by soft soup demand, though fruit/vegetable and wet pet food grew. Adjusted EBIT rose 10% year-over-year to approximately $90 million (estimated) due to normalized operations and cost efficiencies.

Custom Containers: Sales increased 4% year-over-year due to raw material pass-throughs. Volumes declined 8%, partly due to the exit of lower-margin business. Adjusted EBIT reached record levels, driven by favorable price-cost dynamics and footprint optimization savings.

Fourth Quarter 2026:

• Adjusted EPS estimated at $0.76–$0.86 per diluted share (vs. $0.67 in prior year).
• Assumes comparable volumes across all segments.

Full Year 2026:

• Adjusted EPS raised to $3.83–$3.93 (midpoint up 4% vs. $3.72 in 2025).
• Expects low single-digit adjusted EBIT growth.
• Confirmed free cash flow estimate of approximately $450 million (including ~$310 million capex).
• Volumes expected to be comparable to prior year across all segments.

Long-Term Outlook:

• Expects another year of organic earnings and modest free cash flow growth in 2027 post-split.

Consumer Demand Softness:

• Continued pressure in food, beverage, home care, and lawn/garden sectors as consumers stretch dollars.
• Specific weakness in soup markets impacting metal container volumes.

Inflationary Pressures:

• Significant resin price increases (>50%) and steel/aluminum inflation creating margin headwinds.
• Lag in pass-through mechanisms for certain dispensing products requiring proactive pricing actions.

Geopolitical and Regional Volatility:

• Adverse currency impacts.
• Ongoing softness in Brazil affecting volume mix and profitability.
• Unplanned macro risks such as Middle East conflicts disrupting supply chains or demand.

Q: Baird asked about the timeline for DSC margin stabilization after six quarters of decline.

A: Adam Greenlee indicated normalization is expected in Q4 2026. While resin and metal closures inflation are largely passed through contractually, other costs have lagged. The company has taken aggressive pricing actions to recover these non-contractual inflationary items, with recovery starting in Q4 and extending into early 2027. This should drive year-over-year organic EBIT growth in DSC for the quarter.

Q: Bank of America asked why volume guidance was revised to 'comparable' rather than growth, specifically regarding soup and custom containers.

A: Greenlee explained that a key soup customer took significant inflation in 2026 and elected to raise prices in Q3, which suppressed volumes. This dynamic is embedded in Q4 guidance with no significant recovery anticipated. In custom containers, challenging consumer behavior in food/beverage and home care continues to suppress volumes. However, the company remains confident in delivering earnings growth without market volume expansion, having beaten guidance for three consecutive quarters.

Q: Raymond James asked about the sustainability of pharma dispensing growth and its contribution to the new Dispensing Solutions segment.

A: Management confirmed pharma is a rapidly growing, regulated business (~$250M revenue) with 3-5 year development pipelines. Growth seen in Q3 was consistent with expectations, not just timing shifts. Post-split, this high-growth, high-margin healthcare portfolio will reside entirely in Silgan DS, while slower-growing food/beverage closure volumes move to Silgan MCC, thereby enhancing the long-term growth profile of the Dispensing Solutions entity.

Q: JP Morgan asked about the magnitude of free cash flow growth expected in 2027.

A: CFO Shawn Fabry stated they expect modest free cash flow growth in 2027, driven by volume growth and continued working capital initiatives. No specific numerical guidance was provided for 2027 FCF, but the company emphasized ongoing focus on optimizing capital expenditure and cash conversion efficiency.

Q: Deutsche Bank asked about the nature of incremental investments required ahead of the Trivium closing in mid-2027.

A: Adam Greenlee clarified that investments will primarily be incremental capital expenditures rather than earnings expenses. These will include minor investments in products, operating facilities, and teams to ensure both entities are prepared for successful separation and operation under the new structure. The goal is to set the businesses up for long-term success without distracting from current operational execution.